Updates on Scheme of Amalgamation
Sun Pharmaceutical Industries Ltd has informed BSE that the Hon'ble High Court of Gujarat, at Ahmedabad at its hearing held on July 30, 2015 has approved the Scheme of Amalgamation of Sun Pharma Global Inc. (SPGI), wholly-owned subsidiary of the Company, into Sun Pharmaceutical Industries Limited (SPIL) with effect from the appointed date of January 01, 2015.... Higher costs are eroding our competitive edge: Suns Shanghvi
High inflation rates are causing India to lose its competitive cost advantage, said Dilip Shanghvi, Managing Director, Sun Pharma. The challenge is how to grow businesses in India in such a way th... Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Jayant S Sanghvi has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE Sun Pharma May File New Drug Application With US Regulator
Sun Pharma, India's largest drug maker, may file application for a new drug with the US Food and Drug Administration in next two to three years, its managing director Dilip Shanghvi said on Thursday. Sun Pharma to announce first quarter results on August 11, 2015
Sun Pharmaceutical Industries Ltd has informed BSE regarding a Press Release dated July 29, 2015 titled "Sun Pharma to announce first quarter results on August 11, 2015". Q1 results on August 11, 2015
Sun Pharmaceutical Industries Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on August 11, 2015, inter alia, to consider and take on record the Unaudited Financial Results of the Company for the first quarter and three months ended June 30, 2015.Further, the window closure for trading by designated persons as per Insider Trading Rules of the Company will be from July 31, 2015 to August 13, 2015 (both days inclusive). Correction shaves off Rs 60,600 cr m-cap of top seven cos
Seven of the top 10 most valued Indian companies saw a combined erosion of Rs 60,600 crore in market valuation last week on account of correction, with Sun Pharma taking the hardest hit. While TCS, HDFC Bank, CIL, ITC, ONGC, Sun Pharma and SBI ... Sun Pharmas open offer to Zenotech shareholders gets tepid response
Just 785 shares have been acquired so far Post Open Offer Status to the Shareholders of Zenotech Laboratories
Citigroup Global Markets India Private Limited ("Manager to the Offer"), on behalf of Sun Pharmaceutical Industries Limited ("Sun Pharma" / "Acquirer"), has informed this Post Offer Announcement to the Shareholders of Zenotech Laboratories Limited (Zenotech / Target Company), pursuant to Regulation 18(12) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (SEBI (SAST) Regulations)... Allotment of equity shares under Sun Employee Stock Option Scheme 2015
Sun Pharmaceutical Industries Ltd has informed BSE that the Allotment Committee of Directors at its meeting held on July 23, 2015, allotted 72,789 (Seventy Two Thousand Seven Hundred and Eighty Nine) equity Shares of the Company of Re. 1/- each on exercise or stock options under the Sun Employee Stock Option Scheme - 2015. The paid-up equity share capital of the Company post allotment is Rs. 24,064,96,137/- (Rupees Two Hundred and Forty Crore Sixty...